Consonance Capital

Civic Eagle, Inc. is a software company that specializes in providing a workflow solution for advocates and policy teams. Founded in 2015 and headquartered in Minnesota, Civic Eagle offers a platform called Enview, which integrates state and federal bills with team communications. This platform enables lobbyists, policy professionals, and government affairs teams to efficiently discover, analyze, and manage legislation without manual effort. By streamlining the process of tracking and working with legislation across the country, Civic Eagle allows policy advocates to concentrate on impactful campaigns, ultimately aiming to foster better democratic outcomes for individuals and communities.

Surrozen, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing targeted regenerative antibodies to enhance tissue and organ repair in response to serious diseases. Founded in 2015, the company specializes in modulating the Wnt pathway, a crucial mediator of tissue regeneration, through its innovative antibody platforms that target specific organs and tissues. Notable programs include SZN-043, designed to stimulate liver regeneration in both acute and chronic liver diseases, and SZN-1326, aimed at repairing damaged epithelial tissue in patients with inflammatory bowel disease. Surrozen's approach extends to multiple organ systems, with potential applications in the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

Rivy is making it easier to finance small and medium sized businesses in Africa. There is a need for financing of $158 bn for SMEs in Nigeria alone. To start, Rivy o helps SMEs access and spend lender capital effectively. During their first full operational year in 2020, the Rivy o co--founders leveraged their domain expertise and founding experience to beat their 2020 goal by 50%.

Silence Therapeutics plc is a biotechnology company based in London, specializing in the discovery and development of innovative RNA therapeutics. The company focuses on utilizing short interfering RNA (siRNA) technology to modulate gene expression and address various medical conditions, including hematology, cardiovascular diseases, and rare metabolic disorders. Its pipeline includes several product candidates, such as SLN124, aimed at treating iron overload disorders by silencing the TMPRSS6 gene, and SLN360, which targets the LPA gene to reduce the risk of cardiovascular diseases. Silence Therapeutics has established strategic collaborations with major organizations, including AstraZeneca, to advance the development of siRNA therapeutics across multiple disease areas. The company leverages its proprietary genetic toolkit and delivery systems to optimize therapeutic outcomes, harnessing the body's natural biological mechanisms for effective treatment.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. The company utilizes its proprietary Dolaflexin platform to create a pipeline of novel ADC candidates designed to improve treatment outcomes for those not responding to traditional therapies. Mersana's lead product candidate, XMT-1536, targets NaPi2b and is currently undergoing Phase I clinical trials for ovarian cancer, non-small cell lung cancer, and other orphan indications. In addition to XMT-1536, the company is advancing several early-stage programs, including XMT-1660, which targets B7-H4, and XMT-2056, a STING agonist ADC. Mersana has established strategic partnerships for research and development, notably with Merck KGaA and Asana BioSciences, to enhance its ADC product portfolio. Founded in 2005, Mersana Therapeutics continues to innovate in the field of oncology therapeutics.

Orsini Healthcare manages the handling and service requirements of pharmaceuticals including dispensing, distribution, reimbursement, case management, and other services to patients with chronic diseases. They help patients, doctors, insurance companies, and manufacturers improve care, processes, and outcomes.

Psychiatric Medical Care, LLC is a Nashville-based company founded in 2003 that specializes in behavioral health management services, particularly for the geriatric population. The company offers a range of solutions, including telepsychiatry, intensive outpatient programs, and adult inpatient units, aimed at treating mental health conditions such as depression, anxiety, mood disorders, and post-traumatic stress disorder. In addition to direct patient care, Psychiatric Medical Care supports hospitals and healthcare partners by providing recruitment, training, and education for clinical staff. The company is committed to enhancing the quality of life for its patients through comprehensive, round-the-clock care and ongoing mental health training.

DX Bako is a healthcare services company that specializes in diagnostic and therapeutic services primarily for podiatric physicians. The company offers a range of specialty laboratory testing, including anatomic pathology, nail DNA testing, and peripheral neuropathy immuno-histochemical testing. Additionally, DX Bako provides proprietary molecular genetic testing and office-dispensed therapeutics. Committed to advancing the field of podiatric dermatology, the company emphasizes education and research, striving to support healthcare providers with actionable information that enhances patient care.

Bako Integrated Physician Solutions is the premier provider of diagnostic and therapeutic services focusing on the skin, soft tissue and bone of the lower extremity. Their pathology team provides not just information, but also intelligence to enable better patient care.

Telesta Therapeutics is a Canadian biopharmaceutical company dedicated to the development, manufacturing, and commercialization of innovative human therapeutics aimed at addressing significant unmet medical needs, particularly in oncology. The company’s lead product, MCNA, has successfully completed a Phase III pivotal study for patients with non-muscle invasive bladder cancer who have not responded to the first-line treatment, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application to the U.S. FDA in June 2015, seeking marketing approval to provide MCNA to patients. The company's mission is to transform the treatment landscape for bladder cancer and enhance the quality of life for those affected by this prevalent disease.

Enclara Pharmacia, Inc. is a comprehensive provider of medications and clinical services tailored for the hospice and palliative care sectors. Founded in 1996 and based in Philadelphia, Pennsylvania, the company specializes in offering a direct-to-patient mail order pharmacy model alongside access to a network of retail pharmacies, including its automated fulfillment and institutional pharmacies. Enclara Pharmacia's services encompass hospice mail order pharmacy solutions, clinical support services, business intelligence tools, and educational resources designed to facilitate compliance with state regulations and enhance medication management. By focusing on operational efficiency and patient-centered care, the company aims to improve the quality of life for patients facing progressive illnesses and supports hospice providers across the United States. In October 2014, Enclara Pharmacia changed its name from excelleRx, Inc., and as of January 2020, it operates as a subsidiary of Eagle RX, Inc.

Kepro is a provider of technology-enabled services focused on care coordination and quality assurance for federal healthcare payers and self-funded organizations. The company specializes in a range of services, including case management, assessments, enrollment, pharmacy management, and absence management. Additionally, Kepro offers maternity management and independent medical reviews, aimed at enhancing healthcare quality and operational efficiency for its clients. The company also provides reporting and analytic services to support and improve client operations, ensuring better outcomes for individuals seeking to remain in their communities.

Enclara Pharmacia, Inc. is a comprehensive provider of medications and clinical services tailored for the hospice and palliative care sectors. Founded in 1996 and based in Philadelphia, Pennsylvania, the company specializes in offering a direct-to-patient mail order pharmacy model alongside access to a network of retail pharmacies, including its automated fulfillment and institutional pharmacies. Enclara Pharmacia's services encompass hospice mail order pharmacy solutions, clinical support services, business intelligence tools, and educational resources designed to facilitate compliance with state regulations and enhance medication management. By focusing on operational efficiency and patient-centered care, the company aims to improve the quality of life for patients facing progressive illnesses and supports hospice providers across the United States. In October 2014, Enclara Pharmacia changed its name from excelleRx, Inc., and as of January 2020, it operates as a subsidiary of Eagle RX, Inc.

Corindus Vascular Robotics, Inc. specializes in the design, manufacture, and commercialization of robotic-assisted systems for interventional vascular procedures. Based in Waltham, Massachusetts, the company offers the CorPath system, which allows physicians to perform catheterization procedures from a radiation-shielded control console, enhancing precision and safety in coronary and peripheral interventions. The CorPath GRX system further enables the robotic-assisted control of guide catheters, guidewires, and balloon/stent devices. Corindus serves various markets, including vascular, coronary, neurointerventional, and structural heart fields, selling its products through a combination of direct sales and partnerships. Founded in 2002, Corindus is a subsidiary of Siemens Medical Solutions USA, Inc. as of late 2019.